DRIO (DarioHealth) Valuation Rank


DRIO DarioHealth Corp DRIO
58 GF Score
Price $7.26
GF Value $7.10
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is DarioHealth Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

DarioHealth Valuation Rank Related Terms

DRIO
58GF Score
DarioHealth Corp DRIO
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is DarioHealth (DRIO) Overvalued in 2026?

Based on GuruFocus' analysis, DarioHealth stock appears to be overvalued. The current stock price of $7.26 is trading 2.2% above its estimated GF Value™ of $7.10. GuruFocus considers DarioHealth to be Fairly Valued.

Key valuation signals for DRIO:

  • Valuation Rank:
  • GF Value™: $7.10 vs. price of $7.26 (2.2% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the DRIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DarioHealth Business Description

Address 322 West 57th Street, New York, NY, USA, 10019
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
58GF Score

Get the complete analysis for DRIO

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.26
Price
$7.10
GF Value